Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Viking Therapeutic (VKTX) PT Raised to $125 at BTIG
March 26, 2024 11:20 AM EDTBTIG analyst Justin Zelin raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $125.00 (from $100.00) while maintaining a Buy rating.
The analyst commented, "Viking is up +~25% (vs +0.75% XBI) this morning following presentation of impressive first in human data for oral VK2735, demonstrating 3.3% pbo adj weight loss in the highest dose cohort (40mg QD, n=7) at 28-days with an... More
Viking (VKTX) Climbs 10% Following Results from Phase 1 Trial of Dual GLP-1/GIP Receptor Agonist VK2735
March 26, 2024 7:09 AM EDTViking Therapeutics (NASDAQ: VKTX) Climbs 10% Following Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 DaysVK2735 Shown to be Safe and Well-Tolerated in 28-Day... More